David Meeker, M.D. has served as a member of our board of directors and our chairman since July 2017. Dr. Meeker has served as Chairman, President and Chief Executive Officer of Rhythm Pharmaceuticals, a biopharmaceutical company, since July 2020. Prior to joining Rhythm Pharmaceuticals, Dr. Meeker was Chief Executive Officer and director of KSQ Therapeutics, Inc., from September 2017 to July 2020 and worked at Sanofi Genzyme from October 2011 to June 2017, in a variety of roles, including President and Chief Executive Officer of Genzyme, a Sanofi Company from October 2011 until January 2016, as a member of Sanofi’s Executive Committee from 2012 to June 2017 and as Executive Vice President and head of Sanofi Genzyme, Sanofi’s specialty care unit with responsibility for rare diseases, multiple sclerosis, oncology and immunology franchises, from January 2016 to June 2017. Prior to the acquisition of Genzyme by Sanofi in 2011, Dr. Meeker worked at Genzyme Corporation, beginning in 1994 as medical director, and held positions of increasing responsibility, ultimately serving as Chief Operating Officer. Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an Assistant Professor of medicine at Ohio State University. Dr. Meeker has served as a director of Rhythm Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since November 2015 and as its chairman of the board since April 2017. He has served as Chairman of Pharvaris, a publicly traded company, since January 2021 . Dr. Meeker has also served as a director of MyoKardia, Inc., a publicly traded biopharmaceutical company, from June 2017 to December 2020. Dr. Meeker holds a medical degree from the University of Vermont Medical School and completed the Advanced Management Program at Harvard Business School in 2000. He completed his internal medicine training at Harvard University’s Beth Israel Hospital and pulmonary/critical care training at Boston University.
What is David P. Meeker's net worth?
The estimated net worth of David P. Meeker is at least $2.71 million as of February 19th, 2025. Dr. Meeker owns 201,281 shares of Trevi Therapeutics stock worth more than $2,711,255 as of December 4th. This net worth estimate does not reflect any other assets that Dr. Meeker may own. Learn More about David P. Meeker's net worth.
How do I contact David P. Meeker?
Has David P. Meeker been buying or selling shares of Trevi Therapeutics?
David P. Meeker has not been actively trading shares of Trevi Therapeutics during the last ninety days. Most recently, David P. Meeker sold 4,555 shares of the business's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $2.93, for a transaction totalling $13,346.15. Following the completion of the sale, the director now directly owns 352,489 shares of the company's stock, valued at $1,032,792.77. Learn More on David P. Meeker's trading history.
Who are Trevi Therapeutics' active insiders?
Are insiders buying or selling shares of Trevi Therapeutics?
In the last year, insiders at the sold shares 2 times. They sold a total of 86,576 shares worth more than $583,493.29. The most recent insider tranaction occured on March, 21st when CEO Jennifer L Good sold 5,263 shares worth more than $34,630.54. Insiders at Trevi Therapeutics own 18.3% of the company.
Learn More about insider trades at Trevi Therapeutics. Information on this page was last updated on 3/21/2025.
